These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1798233)

  • 1. Pathogenesis and correspondence of diabetic retinopathy--approach from polyol metabolism.
    Hotta N; Sakamoto N
    Jpn J Med; 1991; 30(6):626-9. PubMed ID: 1798233
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathy].
    Kojima K; Matsubara H; Mizuno K; Harada T; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Nippon Ganka Gakkai Zasshi; 1985 Feb; 89(2):247-56. PubMed ID: 3923790
    [No Abstract]   [Full Text] [Related]  

  • 3. [Diabetes mellitus and its complications in Japan. Pathogenesis and correspondence of diabetic retinopathy--approach from polyol metabolism].
    Hotta N; Sakamoto N
    Nihon Naika Gakkai Zasshi; 1991 Sep; 80(9):1451-6. PubMed ID: 1761927
    [No Abstract]   [Full Text] [Related]  

  • 4. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs.
    Kasuya Y; Ito M; Nakamura J; Hamada Y; Nakayama M; Chaya S; Komori T; Naruse K; Nakashima E; Kato K; Koh N; Hotta N
    Diabetologia; 1999 Dec; 42(12):1404-9. PubMed ID: 10651257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyol pathway in tissues of spontaneously diabetic Chinese hamsters (Cricetulus griseus) and the effect of an aldose reductase inhibitor, ONO-2235.
    Sekiguchi M; Watanabe K; Eto M; Iwashima Y; Morikawa A; Takahashi M; Ishii K; Makino I
    Comp Biochem Physiol B; 1991; 98(4):637-40. PubMed ID: 1907900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
    Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
    Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogs.
    Kubo E; Mori K; Kobayashi T; Takahashi Y; Yokoi N; Kinoshita S; Kasahara T; Yonezawa H; Akagi Y
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):181-90. PubMed ID: 9572544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].
    Hotta N
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():127-35. PubMed ID: 15999695
    [No Abstract]   [Full Text] [Related]  

  • 9. Polyol pathway and protein kinase C activity of rat Schwannoma cells.
    Kamiya H; Nakamura J; Hamada Y; Nakashima E; Naruse K; Kato K; Yasuda Y; Hotta N
    Diabetes Metab Res Rev; 2003; 19(2):131-9. PubMed ID: 12673781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Conservative therapy of diabetic eye disease].
    Sakamoto N; Sakakibara F; Hotta N
    Nihon Rinsho; 1991 Feb; 49 Suppl():293-300. PubMed ID: 2033817
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
    Hotta N; Kakuta H; Koh N; Fukasawa H; Yasuma T; Awaya S; Sakamoto N
    Diabetes Res Clin Pract; 1991 Oct; 14(1):29-35. PubMed ID: 1748061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of polyol pathway in nonenzymatic glycation.
    Hamada Y; Araki N; Horiuchi S; Hotta N
    Nephrol Dial Transplant; 1996; 11 Suppl 5():95-8. PubMed ID: 9044317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
    Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
    Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
    Steele JW; Faulds D; Goa KL
    Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity.
    Nakamura J; Kasuya Y; Hamada Y; Nakashima E; Naruse K; Yasuda Y; Kato K; Hotta N
    Diabetologia; 2001 Apr; 44(4):480-7. PubMed ID: 11357479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetic complication].
    Iwamoto Y
    Nihon Rinsho; 1991 Sep; 49(9):2136-40. PubMed ID: 1960879
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG.
    Kiyono Y; Kajiyama S; Fujiwara H; Kanegawa N; Saji H
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):438-42. PubMed ID: 15821963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldose reductase in diabetic microvascular complications.
    Chung SS; Chung SK
    Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.